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Clinical data have shown that survival rates vary considerably among brain tumor patients, according to the type and grade of 
the tumor. Metabolite profiles of intact tumor tissues measured with high-resolution magic-angle spinning proton nuclear 
magnetic resonance spectroscopy (HRMAS 1H NMRS) can provide important information on tumor biology and metabolism. 
These metabolic fingerprints can then be used for tumor classification and grading, with great potential value for tumor diag-
nosis. We studied the metabolic characteristics of 30 neuroepithelial tumor biopsies, including two astrocytomas (grade I), 12 
astrocytomas (grade II), eight anaplastic astrocytomas (grade III), three glioblastomas (grade IV) and five medulloblastomas 
(grade IV) from 30 patients using HRMAS 1H NMRS. The results were correlated with pathological features using multivari-
ate data analysis, including principal component analysis (PCA). There were significant differences in the levels of 
N-acetyl-aspartate (NAA), creatine, myo-inositol, glycine and lactate between tumors of different grades (P<0.05). There were 
also significant differences in the ratios of NAA/creatine, lactate/creatine, myo-inositol/creatine, glycine/creatine, 
scyllo-inositol/creatine and alanine/creatine (P<0.05). A soft independent modeling of class analogy model produced a predic-
tive accuracy of 87% for high-grade (grade III–IV) brain tumors with a sensitivity of 87% and a specificity of 93%. HRMAS 
1H NMR spectroscopy in conjunction with pattern recognition thus provides a potentially useful tool for the rapid and accurate 
classification of human brain tumor grades. 
neuroepithelial tumor, grade classification, high-resolution magic-angle spinning nuclear magnetic resonance (HRMAS 
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Brain tumors are associated with poor survival and high 
recurrence rates; less than 30% of adult patients survive for 
five years after diagnosis of a primary malignant brain tu-
mor [1–4]. Gliomas such as astrocytomas and glioblastomas 
account for about 45% of all primary human brain tumors 
seen in the clinic, with incidences of around 5–10 per 
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100000 of the general population [5]. Early detection and 
accurate diagnosis are therefore vitally important for their 
appropriate treatment. The clinical diagnosis of brain tu-
mors currently relies almost exclusively on the pathological 
evaluation of morphological changes in tissue specimens. 
However, the diagnosis of many malignant tumors, espe-
cially neuroepithelial tumors (e.g., oligodendroglioma, me-
dulloblastoma), remains a challenge for clinicians and neu-
ropathologists [6–8].  
Modern diagnostic techniques such as X-ray computed 
tomography [9], magnetic resonance imaging [10,11], and 
positron-emission tomography [12,13] form the bases for 
patient treatment plans, and have all been used clinically to 
characterize human brain tumors. However, the techniques 
are often used to identify and assess tumor size, and directly 
detect tumor site and location, and thus remain complemen-
tary to histopathology in terms of clinical diagnosis. 
In vivo 1H magnetic resonance spectroscopy (MRS) [14–17] 
and in vitro 1H nuclear magnetic resonance (NMR) spectros-
copy of tissue extracts [18–21] have provided more informa-
tion on metabolites correlated with the histopathology of tis-
sue specimens, and have helped to improve our understand-
ing of tumor biology, with benefits in terms of the diagnostic 
accuracy of human brain tumors. However, although in vivo 
1H MRS [14–17] is the only non-invasive in vivo metabo-
lite-detection technique, its limited spectral resolution and 
detection sensitivity means that it can often only detect a few 
metabolites, such as lipids (Lip), total creatine (tCre), total 
choline (tCho), lactate (Lac), glutamate (Glu) (or glutamine, 
Gln), and N-acetyl-aspartate (NAA). Furthermore, the spec-
tral baseline and signal-to-noise ratio may be inadequate for 
quantitative analysis. By contrast, although in vitro 1H NMR 
spectroscopy of tissue extracts [18–21] has a much higher 
resolution, its use remains questionable: (i) The extraction 
method requires large amounts of tissue (at least 50 mg); (ii) 
the destructive nature of the extraction may alter the corre-
sponding spectrum to an unknown degree, although the 
length of the extraction procedure is acceptable (>24 h); (iii) 
the extraction method usually discriminates between metabo-
lites on the basis of solubility in a particular solvent, and pre-
vents the direct observation of semi-mobile membrane lipids. 
Thus, complementary methods are needed for the rapid and 
direct extraction of further information on the metabolic 
characteristics of tumors tissues. 
High-resolution magic-angle spinning (HRMAS) 1H NMR 
spectroscopy of intact biological tissues has recently proven 
to be a useful technique for the rapid classification and 
grading diagnosis of tumors [22–25]. This technique only 
requires minimal sample preparation (about 5 min), and 
allows the observation of most of the tissue metabolites and 
their dynamic interactions in small sample (around 10 mg). 
Furthermore, the shorter acquisition time (<20 min) of the 
procedure considerably reduces the risk of chemical altera-
tions of the biopsy and prevents extensive tissue degradation 
[26]. When used in conjunction with multivariate data analy-
sis (MVDA)-based pattern recognition (PR) methods, such as 
principal component analysis (PCA), semi-automated NMR 
methods have become an important part of the ex vivo tissue 
metabonomics platform, and currently provides the only 
known non-invasive tissue metabonomics technique. These 
advantages are already being exploited [27,28] to provide a 
convenient, rapid and accurate complementary method to 
biochemical studies for the diagnosis and classification of 
human tumors. 
In this study, we used HRMAS 1H NMRS methods in 
conjunction with MVDA to analyze the metabonomic char-
acteristics of 30 human neuroepithelial tumors with the aims 
of further understanding the differences between various 
grades of tumors at the metabolic level, and exploring the 
feasibility of a new grade-classification technique to com-
plement conventional techniques.  
1  Materials and methods 
1.1  Collection and pathological assessment of brain 
tissue samples 
Two astrocytoma (grade I), 12 astrocytoma (grade II), eight 
anaplastic astrocytoma (grade III), three glioblastoma 
(grade IV) and five medulloblastoma (grade IV) specimens 
were obtained from 30 patients at the Department of Neu-
rosurgery, Tongji Hospital, Tongji College of Medicine, 
Huazhong University of Science and Technology, and 
Zhongnan Hospital, Medical College of Wuhan University. 
Each specimen was divided into two parts after craniotomy 
(<30 min of tissue collection). One part was fixed in 10% 
neutral buffered formalin solution and embedded in paraffin, 
and used for routine pathological examination. Tissue sec-
tions (5 μm thick) were stained with hematoxylin and eosin 
(H&E) for microscopic examination, and characterized ac-
cording to the 2000 revised World Health Organization crite-
ria for brain tumors. The other part to be used for MAS was 
immediately snap-frozen in liquid nitrogen and subsequently 
stored at −80°C until HRMAS 1H NMRS measurement. This 
study was reviewed and approved by the local ethics com-
mittee and informed consent for the use of their tissue sam-
ples for research purposes was obtained from all patients. 
All brain tumor samples were classified into five groups, 
based on type and grade. Patient data are summarized in 
Table 1. The patients had a wide age range (10–71 years), 
with a higher percentage of males (n=20) than females 
(n=10). However, based on the limited number of cases, no 
obvious age-related trends were detectable, except for the 
observation that medulloblastomas occurred more fre-
quently in childhood and adolescence.  
1.2  HRMAS 1H NMR spectroscopy of brain tumor 
tissues 
Each individual tumor sample (20–30 mg) was rinsed in  
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Table 1  Histopathological data for 30 brain tumor specimens from 30 patients 
Gender Age of patient (year) 




Group 1 (n=2) astrocytoma I 1 1  36–63 50±19.1 
Group 2 (n=12) astrocytoma II 8 4  21–63 38±12.6 
Group 3 (n=8) astrocytoma III 3 5  36–71 49±11.7 
Group 4 (n=3) glioblastoma IV 3 0  22–41 32±9.5 
Group 5 (n=5) medulloblastoma IV 5 0  10–32 19±9.4 
 
D2O saline at low temperature (4°C), and placed into a 
4-mm quartz rotor, especially designed for HRMAS spec-
troscopy. The total preparation time for each sample was 
less than 5 min. All HRMAS 1H NMR spectra were ac-
quired at 298 K using the methanol method [29] to calibrate 
the temperature of the HRMAS probe on a Varian INVOA 
599.906 MHz spectrometer (California, USA) equipped 
with a standard gHX Nanoprobe (California, USA) at a spin 
rate of 2 kHz. Two 1H NMR spectra for each sample were 
recorded using one-dimensional single-pulse sequence and 
standard Carr-Purcell-Meiboom-Gill (CPMG) spin-echo 
pulse sequence [RD-90°-(τ-180°-τ)n-ACQ] [26,30]. Water 
signals were pre-saturated in both cases by weak continuous 
wave irradiation on water resonance during the recycle de-
lay (RD). The 90° pulse length was adjusted to 4.2–5.7 μs 
for each individual sample, and 128 scans were collected 
using 16 k data, a recycle delay of 2 s and a spectral width 
of 12 kHz for all samples. In the case of the CPMG experi-
ments, a total spin-spin relaxation delay (2nτ) (τ = (240–250) 
μs) of 32 ms was used for all samples. The total acquisition 
time for each sample was less than 20 min. 
The free induction decays were multiplied by an expo-
nential window function with a 1.0-Hz line-broadening fac-
tor prior to Fourier transformation. All sample spectra were 
manually phase- and baseline-corrected using XWINNMR 
2.0 software (Bruker Analytik, Germany) after converting 
the data into the correct format (whole spectrum). The pro-
ton chemical shifts were referenced internally to the centre 
of the lactate methyl doublet at 1.33 ppm. 
When more cases are studied, simple comparisons be-
tween spectra are inadequate for obtaining all the useful 
information on tissue metabolite changes because of the 
spectral complexity and the large quantity of data. The most 
effective method is thus to provide an average spectrum for 
each group of tumors. The average spectrum for each group 
can be obtained as follows: The spectral region (δ 0.50–4.50) 
is divided into 4000 buckets with a uniform width of 0.001 
ppm. The integral of each bucket is then normalized to the 
total integrals over the entire region (δ 0.50–4.50). These 
normalized spectra for all sub-groups of tumors are aver-
aged numerically. 
1.3  Data reduction and PCA 
Traditional methods of spectral analysis use peak heights or 
peak areas, while PCA uses the whole spectrum. Because of 
the presence of spinning sidebands resulting from hardware 
restriction of the spinning rate to 2 kHz, and relatively few 
and signals in the aromatic region, only signals between   
δ 0.50 and 4.50 were selected for PCA. Each sub-spectrum 
was divided into 4000 regions with a uniform width of 
0.001 ppm. The signal intensities in each region were inte-
grated, and each integrated region was normalized by the 
sum of all integrals over the entire sub-spectrum.  
To determine if it was possible to distinguish between 
various grades of brain tumors using HRMAS 1H NMR 
spectra data, PCA and partial least squares-discriminant 
analysis (PLS-DA) were carried out with mean-center scal-
ing using SIMCA-P 10.0 software (Umetrics, Sweden). 
Processed data were visualized by score plots and regres-
sion coefficient (or loading) plots, where each point on the 
score plot represented the metabonome of an individual 
sample, while each bin on the regression coefficient (load-
ing) plot represented a single spectral region (or chemical 
shift) contributing to the separation [27,30–32].  
1.4  Pattern recognition 
The classification and prediction of various grade tumors 
was maximized using a supervised pattern recognition 
method: Soft Independent Modeling of Class Analogy 
(SIMCA) was performed using various class information 
for tumors as defined “Y” variables. The data set was di-
vided into “training” and “test” sets, and the principal com-
ponents of each class in the training set were calculated. 
The class membership of set samples was assigned accord-
ing to their position within the calculated boundaries of the 
training set group, specified in a Cooman’s residual plot [27]. 
In addition, orthogonal signal correction (OSC) was used to 
optimize the separation [33]. An orthogonal partial least 
squares (OPLS) model was used to predict the grade classi-
fication of tumors. OPLS is an extension to the supervised 
PLS method featuring an integrated OSC filter to remove 
variability not relevant to class separation.  
In the present study, all 30 tumor samples were initially 
assigned to two classes. All 14 samples from grade I and 
grade II astrocytomas constituted the low-grade class (class 
1), whereas the remainder from grade III astrocytomas, 
glioblastomas and medulloblastomas constituted the high-     
grade class (class 2). Half of the samples from each class 
were selected as the ‘training’ set, while the remaining 
samples were used as the ‘test’ set. SIMCA models were 
 Chen W X, et al.   Sci China Life Sci   July (2011) Vol.54 No.7 609 
 
established based on HRMAS 1H NMR data (or filter data). 
When there were only a few samples in the dataset, the 
‘leave-one-out’ method, in which each sample is excluded 
in turn from the ‘training’ data and used as the ‘test’ datum, 
was used to test the discriminant function. 
1.5  Statistical analysis  
The absolute concentrations of metabolites are difficult to 
quantify using HRMAS NMR spectra, and the relative con-
centrations were therefore defined as the ratio of the indi-
vidual metabolite signal integrals over that of the total spec-
tra. Every NMR peak was therefore normalized to the sum 
of the total spectrum, and the resulting data were used for 
statistical analysis. 
The normalized integrals of some important metabolites 
for 30 human brain tumors and their ratios relative to Cre  
(δ 3.93) were subjected to two-tailed analysis of variance 
(ANOVA) using the statistical software SPSS 10.0 (Statis-
tical Package for Social Science, SPSS Inc., USA). Changes 
in metabolite levels were considered to be statistically sig-
nificant when P<0.05. 
2  Results 
2.1  Pathological assessment and photomicrographs of 
tumor samples  
Figure 1 shows histological sections (H&E stain) of normal 
tissue, grade I, II, and III astrocytomas, a glioblastoma 
(grade IV) and a medulloblastoma (grade IV). The number of 
tumor cells rapidly increased with increasing tumor grade. 
Compared with normal tissue (Figure 1A), the grade I–II 
astrocytomas (Figure 1B and C) showed clear increases in 
the number of tumor cells with no mitosis, while the grade 
III astrocytoma (Figure 1D) showed further increases in 
tumor cells accompanied by a visibly invasive schistosome 
ovum. The grade IV glioblastoma (Figure 1E), regarded as a 
grade IV astrocytoma, displayed marked endothelial prolif-
eration and mitosis. The grade IV medulloblastoma (Figure  
 
 
Figure 1  Photomicrographs (H&E stain) of normal tissue and five brain tumor specimens. A, Normal tissue (200×). B, Astrocytoma (200×, grade I). 
C, Astrocytoma (200×, grade II). D, Astrocytoma (200×, grade III). E, Glioblastoma (200×, grade IV). F, Medulloblastoma (200×, grade IV). 
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1F) was characterized by sheets of densely packed cells 
with more abundant cytoplasm and numerous mitoses.  
2.2  HRMAS 1H NMR spectroscopy of brain tumors 
Figure 2 shows the HRMAS 1H NMR spectra acquired us-
ing a CPMG pulse sequence at a spinning rate of 2 kHz, 
corresponding to the above H&E samples. Several metabo-
lite resonances were detected from the spectra. Spectral 
assignments were confirmed by 1H-1H total correlation 
spectroscopy HRMAS 2D NMR spectra (data not shown), 
together with published data [18,20,25,34–36]. For astrocy-
tomas (Figure 2B–D), the levels of remainder Lip (δ 0.92), 
Lac (δ 1.33), alanine (Ala, δ 1.48) and scyllo-inositol (sI,  
δ 3.35) increased with increasing tumor grade, while the 
levels of NAA (δ 2.03), myo-inositol (mI, δ 3.62) and Cre  
(δ 3.04) decreased. Higher levels of glycine (Gly, δ 3.56) 
and Lip (δ 0.92) together with lower levels of NAA, phos-
phocholine (PC, δ 3.22) and glycerophosphocholine (GPC, 
δ 3.23) were the principal characteristics of glioblastomas 
(Figure 2E). Higher levels of taurine (Tau, δ 3.43), PC and 
GPC, together with lower levels of Lac, were the chief 
characteristics of medulloblastomas (Figure 2F). 
Figure 3 shows the average HRMAS 1H NMR spectra 
(mean±SD) for the five groups of tumor tissues with various 
grades recorded by CPMG pulse sequences. Apart from the 
intense fatty acid signals, which were not completely sup- 
pressed by the CPMG pulse sequence because of the short 
relaxation time (32 ms), a number of metabolite differences  
 
 
Figure 2  HR-MAS 
1
H NMR spectra of six brain specimens acquired 
from CPMG pulse sequence at a spin rate of 2 kHz. A, Normal tissue. B, 
Astrocytoma (grade I). C, Astrocytoma (grade II). D, Astrocytoma. E,  
Glioblastoma (grade IV). F, Medulloblastoma (grade IV). 
 
Figure 3  Average HRMAS 1H NMR spectra for 30 tumor samples ob-
tained by CPMG pulse sequence at a spinning rate of 2 kHz. A, Astrocy-
tomas (grade I). B, Astrocytomas (grade II). C, Astrocytomas (grade III). D, 
Glioblastomas (grade IV). E, Medulloblastomas (grade IV). *, The real line 
and dashed line represent mean and standard deviation (SD) of the spectra  
for each grade group, respectively. 
could be detected between the spectra of the various grades 
of tumors. The levels of Lip and Ala in grade II and III as-
trocytomas were higher than in grade I astrocytomas (Figure 
3A), while the levels of NAA, mI, Cre, PC and GPC were 
lower (Figure 3B and C). The levels of Lip and Tau in grade 
IV glioblastomas were higher than in grade I tumors, but the 
levels of Lac and Cre were much lower (Figure 3D). How-
 Chen W X, et al.   Sci China Life Sci   July (2011) Vol.54 No.7 611 
 
ever, compared with grade II–III astrocytomas and grade IV 
glioblastomas, the levels of mI, Tau, Gly, PC, GPC and 
aspartate (Asp) in grade IV medulloblastomas were rela-
tively high, whereas the levels of Lac and Cre were low 
(Figure 3E). 
2.3  PCA of HRMAS 1H NMR data 
Figure 4 shows PLS-DA score plots and regression coeffi-
cient plots of HRMAS 1H NMR spectra for various groups 
of tumors. The first principal component (PC1) in Figure 
4A accounted for 24.4% of all the variations in the MAS 
spectra, and showed good separation between grade I–II 
(group 1–2) and grade III (group 3) astrocytomas. Corre-
spondingly, the regression coefficients in Figure 4B indicate 
that the levels of NAA, Cre, GPC and mI in grade I–II as-
trocytomas (group 1–2) were relatively high but the levels 
of Lac and PC were lower, compared with grade III astro-
cytomas (group 3). The PC1 in Figure 4C explained 27.8% 
of all the variations in the MAS spectra and also showed 
good separation between grade I–II (group 1–2) and grade 
IV (group 4–5) tumors. Compared with grade IV tumors, 
the positive values of the regression coefficients in Figure 
4D indicate that the levels of Lac, Cre, Cho and GPC in 
grade I–II tumors were higher, whilst the negative values 
indicated that the levels of Gly and PC were lower. Simi-
larly, the PC1 in Figure 4E (explaining 29.8% variations) 
showed a good separation between grade III (group 3) and 
grade IV (group 4–5) tumors. The regression coefficients in 
Figure 4F show that the levels of Lac, Cre, Cho and GPC in 
grade III astrocytomas (group 3) were higher, but the levels 
of mI and PC were lower, compared with grade IV tumors 
(group 4–5). Finally, the PC1 in Figure 4G (explaining 
23.2% variation) also showed good separation between 
glioblastomas (group 4) and medulloblastomas (group 5), 
whereas the PC1 in Figure 4I (explaining 33.3% variation) 
showed good separation between grade I (group 1) and 
grade II astrocytomas (group 2). The regression coefficients 
of PC1 (Figure 4H and J) showed the important contribu-
tions of some metabolites to the differentiation between 
groups. 
2.4  SIMCA analysis of HRMAS 1H NMR data 
Figure 5 shows an OPLS model that can be used to predict 
the class membership of the tumor samples. The PC1 ac-
counted for 66% of all the variations in the spectra, and 
showed a clear separation between class 1 and class 2. The 
OPLS score plot was characterized by the following pa-
rameters: R2Y=0.96 and Q2=0.95. The high Q2 value indi-
cated the good predictive capabilities of the model. 
Figure 6 shows the Cooman residual plot for membership 
of class 1 and class 2. This plot is divided into four regions 
based on the 95% confidence limits for both classes. Six of 
seven tested tumor samples in class 1 (upper left region) 
were correctly classified as low-grade, while seven of eight 
tested tumor samples in class 2 (lower right region) were 
classified as high-grade. The accuracy of each class predic-
tion using the SIMCA model was almost 87%. Furthermore, 
the present SIMCA model predicted the presence of grade 
III–IV brain tumors (class 2) with a sensitivity of 87% and a 
specificity of 93%. The classification results using the 
“leave-one-out” method are summarized in Table 2. For 
instance, the percentage of each class correctly classified for 
filter data was 100%. 
2.5  Statistical analysis 
Changes in metabolite levels and metabolite/Cre ratios 
(Figures 3 and 4) were analyzed by two-tailed ANOVA, and 
the results are summarized in Tables 3 and 4. As shown in 
Table 3, the levels of some metabolites gradually decreased 
with increasing tumor grade (i.e., from grade I to grade IV), 
whereas the levels of other metabolites gradually increased 
with increasing tumor grade. These metabolites mainly in-
cluded mI, Cre, PC, GPC, Gly, Tau and Asp. Furthermore, 
significant differences (P<0.05) in levels of NAA, Cre, mI, 
Gly and Lac were observed between groups (Table 3). No 
significant differences in levels of Tau, sI, Asp, Glu, Ala, 
valine, Lip or tCho (Cho, PC and GPC) were found. There 
were significant differences in NAA/Cre, Lac/Cre, mI/Cre, 
Gly/Cre, sI/Cre and Ala/Cre ratios between groups (P<0.05) 
(Table 4). 
3  Discussion 
The poor survival rate of patients with malignant brain tu-
mors means that improved understanding leading to their 
early detection and accurate grade classification is vitally 
important in terms of determining their prognosis and ap-
propriate treatment. In the present study, we observed clear 
differences between HRMAS 1H NMR spectra correlated 
with the histopathological specimens. However, the com-
plexity of the spectra and the large number of samples make 
simple visual inspection difficult, and small differences in 
spectra between different samples in the same group may be 
especially difficult because of microheterogeneity among 
individuals [37] and/or inconsistence of sampling sites. Ef-
fective methods for rapidly observing differences between 
spectra in large numbers of tumor tissue samples are there-
fore needed. 
This study therefore used two methods, average spectra 
and PCA of various group samples, to maximize the scope 
for differentiating among tumors and classifying tumors. 
Changes in levels of some metabolites, including Lac, mI, 
Cre, Gly and tCho (Cho, PC and GPC), were clearly dem-
onstrated between different groups by examining average 
spectra. Regression coefficient plots of PLS-DA showed the 
important contributions of some metabolites to the separa- 
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Figure 4  Comparison of PLS-DA score plots and regression coefficient plots of HRMAS 1H NMR spectra from 30 tumor samples between different grade 
tumors. A and B, PLS-DA score plot (A) and regression coefficient plot (B) of PC1, respectively, produced using only groups 1–2 and 3. C and D, PLS-DA 
score plot (C) and regression coefficient plot (D) of PC1, respectively, produced using only groups 1–2 and 4–5. E and F, PLS-DA score plot (E) and regres-
sion coefficient plot (F) of PC1, respectively, produced using only groups 3 and 4–5. G and H, PLS-DA score plot (G) and regression coefficient plot (H) of 
PC1, respectively, produced using only GBM and MED. I and J, PLS-DA score plot (I) and regression coefficient plot (J) of PC1, respectively, produced 
using only AST I and AST II. ■, Group 1–2; △, group 3; *, group 4–5; ●, GBM (glioblastoma); ○, MED (medulloblastoma); ◇, AST I (astrocytoma I);  
◆, AST II (astrocytoma II). 
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Figure 5  PC1 vs. PC2 score plots of filtered-PLS model obtained from 
HR MAS 1H NMR spectra of 30 tumors samples. ◆, Low-grade (I–II)  
brain tumors; ▲, high-grade (III–IV) brain tumors. 
 
Figure 6  Cooman plot of HR MAS 1H NMR spectra for 30 tumor sam-
ples from low-grade brain tumors from the “training” set ( ) ◆ and the 
“test” set ( ), and high◇ -grade brain tumors from the “training” set ( ) ▲  
and the “test” set ( ).△  
Table 2  Classification results for the various models before and after OSC filter dataa) 
Number of cases assigned to each class (PLS model)* Number of cases assigned to each class (OPLS model)# 
Grade class Total cases 
Class 1 Class 2 
 
Class 1 Class 2 
Class 1 14 12 2  14 0 
Class 2 16 0 16  0 16 
a) *, Percentage of classes correctly classified: 93% (28/30); #, percentage of classes correctly classified: 100% (30/30). 
Table 3  Selected metabolite concentrations (percentages of normalized integrals) calculated from HRMAS 1H NMR spectra for differentiating between 
different grade tumorsa) 
AST I (n=2) AST II (n=12) AST III (n=8) GBM (n=3) MED (n=5) 
Metabolite (chemical shift) 
Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD 
P-value* 
NAA (δ 4.38) 1.26±0.25 0.90±0.24 0.56±0.21 0.88±0.31 0.91±0.22 <0.01 
lactate (δ 4.12) 1.90±0.22 1.46±0.26 1.74±0.28 1.16±0.44 1.26±0.40 <0.05 
creatine (δ 3.93) 2.76±0.59 1.64±0.55 1.10±0.44 0.90±0.38 1.04±0.38 <0.001 
myo-inositol (δ 3.62) 5.75±0.50 2.94±0.86 2.64±0.80 2.17±0.45 3.62±1.20 <0.001 
glycine (δ 3.56) 0.67±0.32 0.77±0.18 0.93±0.23 0.69±0.06 1.37±0.74 <0.05 
taurine (δ 3.43) 0.41±0.18 0.47±0.19 0.51±0.15 0.76±0.82 0.81±0.47 0.20−0.30 
scyllo-inositol (δ 3.35) 0.52±0.47 0.33±0.15 0.44±0.11 0.31±0.08 0.43±0.21 0.40−0.50 
PC+GPC (δ 3.22) 5.61±0.12 4.88±1.64 4.18±1.13 3.59±0.37 4.63±2.82 0.60−0.70 
choline (δ 3.20) 1.53±1.36 1.82±0.71 1.71±0.63 1.33±0.26 1.07±0.68 0.30−0.40 
tCho (δ 3.21) 7.14±1.25 6.69±2.06 5.89±1.45 4.92±0.50 5.70±3.39 0.60−0.70 
aspartate (δ 2.82) 0.06±0.08 0.18±0.07 0.24±0.11 0.26±0.12 0.48±0.47 <0.08 
glutamine (δ 2.46) 1.34±0.49 0.87±0.37 0.91±0.35 0.66±0.37 0.75±0.54 0.40−0.50 
glutamate (δ 2.35) 1.09±0.08 1.24±0.34 1.21±0.25 1.19±0.30 1.40±0.57 0.80−0.90 
alanine (δ 1.48) 0.69±0.33 0.55±0.29 0.89±0.33 0.85±0.46 0.70±0.16 0.10−0.20 
valine (δ 1.05) 0.19±0.21 0.21±0.07 0.26±0.10 0.19±0.05 0.19±0.11 0.60−0.70 
lipid (δ 0.92) 3.18±1.32 4.52±1.48 3.90±1.02 5.28±1.52 3.29±1.44 0.20−0.30 
a) Abbreviations: NAA, N-acetyl aspartate; PC, phosphocholine; GPC, glycerophosphocholine; tCho, includes choline, PC and GPC; AST, astrocytoma; 
GBM, glioblastoma; MED, medulloblastoma. *, P<0.05, two-tailed ANOVA method. 
 
tion of groups. The present HRMAS study thus provides 
more information on metabolites correlated with the histo-
pathology of tissue specimens, increasing the chances of 
identifying key molecular pathways and so improving our 
understandings of tumor biology. This in turn will aid the 
accurate classification and grading of human brain tumors. 
The relationships between changes in metabolites and grade 
classification of brain tumors are elucidated below. 
Some studies have reported the use of in vivo MRS, and 
in vitro NMRS and MAS NMRS to distinguish between 
various grades of brain tumors, and the results are summa-
rized in Table 5. The limited spectral resolution and detec-
tion sensitivity of in vivo 1H MRS studies [14–17,34,38], 
mean that signals for Cho, PC and GPC were often collec- 
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tively reported as “tCho”, while the signals for Glu and Gln 
were often reported together as GLX (δ 2.4, 3.7). Signals 
for Gly (δ 3.56) might be mistakenly assigned as mI. How- 
ever, the present MAS study resolved the signals for Glu  
(δ 2.35) and Gln (δ 2.46), allowing them to be considered 
separately, while PC (δ 3.22) and GPC (δ 3.23) could be 
resolved using curve-fitting methods. The significant 
changes in NAA, Cre, mI, Gly and Lac were consistent with 
the above in vivo studies, and the significant differences in 
metabolite/creatine ratios between groups were also consis-
tent with these studies, except in the case of sI/Cre, which 
was observed for the first time (Tables 4 and 5). No signifi-
cant differences in tCho, Ala and Lip levels were found, 
possibly because the levels of PC, GPC and Lip decreased 
(and/or increased) as a result of necrosis [14,39,40] in 
high-grade tumors, such as glioblastomas. 
Previous in vitro 1H NMRS studies [36,41,42] found no 
significant differences in NAA and Cre levels [36,41] be-
tween lower- and higher-grade brain tumors. No informa-
tion on lipid levels was reported, because traditional tissue 
extraction methods usually remove lipophilic lipids. The 
current study thus detected significant differences in more 
metabolite concentrations and ratios than previous in vitro 
studies [36,42] (Table 5).  
Finally, in ex vivo MAS studies, Cheng et al. [43] only 
observed significant differences in Cho (δ 3.20) levels and 
the mI/Cre ratios (δ 4.05) between three astrocytomas and 
eight glioblastomas. Furthermore, the signal peak (δ 4.05) 
was simply assigned to inositol, though the signals were 
mainly generated by Cho and mI. Wilson et al. [44] recently 
found significant differences in levels of Cre, Gln, Tau, 
phosphoethanolamine (δ 3.98) and PC between 12 glial 
tumors (10 pilocytic astrocytomas and two ependymomas) 
and 17 primitive neuroectodermal tumors (nine medul-
loblastomas, seven neuroblastomas, and one supratentorial 
primitive neuroectodermal tumor); however, all the tissue 
samples in their study were resected from 29 pediatric pa-
tients, while most of the samples in the current study were 
from adults. The present study thus detected significant dif-
ferences in levels and ratios of more metabolites between 
groups, compared with previous MAS studies [43,44] (Ta-
ble 5). This suggests that HRMAS 1H NMRS can act as a 
valuable adjunct to current neuropathological techniques 
and may increase the diagnostic accuracy of human brain 
tumors. 
Regarding the grade classification of brain tumors, some 
studies have reported relatively high predictive abilities of 
NMRS combined with PR methods such as linear discrimi-
nant analysis [16,17,41, 44,45] and neural networks [18] for 
differentiating between various tumors. Compared with  
Table 4  Selected metabolite/creatine ratios (δ 3.93) calculated from HRMAS 1H NMR spectra for differentiating between different grade tumorsa) 
AST I (n=2) AST II (n=12) AST III (n=8) GBM (n=3) MED (n=5) 
Metabolite ratio (chemical shift) 
Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD 
P-value* 
NAA/Cre (δ 4.38) 0.46±0.01 0.61±0.28 0.56±0.19 1.11±0.54 0.94±0.29 <0.05 
lactate/Cre (δ 4.12) 0.71±0.23 0.97±0.34 1.76±0.59 1.55±1.20 1.33±0.58 <0.05 
myo-inositol/Cre (δ 3.62) 2.15±0.64 1.88±0.51 2.61±0.90 2.63±1.04 3.85±1.95 <0.05 
glycine/Cre (δ 3.56) 0.26±0.17 0.53±0.26 0.96±0.41 0.88±0.41 1.65±1.54 <0.05 
taurine/Cre (δ 3.43) 0.16±0.10 0.35±0.33 0.50±0.18 1.22±1.65 0.82±0.41 0.10−0.20 
scyllo-inositol/Cre (δ 3.35) 0.21±0.22 0.21±0.10 0.44±0.18 0.41±0.28 0.49±0.34 <0.05 
(PC+GPC)/Cre (δ 3.22) 2.08±0.40 3.17±1.19 4.07±1.13 4.62±2.47 5.49±5.02 0.30−0.40 
choline/Cre (δ 3.20) 0.62±0.63 1.20±0.53 1.79±1.00 1.65±0.81 1.35±1.40 0.40−0.50 
tCho/Cre (δ 3.21) 2.70±1.03 4.38±1.53 5.85±2.01 6.27±3.26 6.83±6.37 0.30−0.40 
aspartate/Cre (δ 2.82) 0.02±0.02 0.14±0.11 0.25±0.16 0.34±0.21 0.66±0.87 0.10−0.20 
glutamine/Cre (δ 2.46) 0.52±0.29 0.59±0.39 0.87±0.26 0.79±0.44 0.69±0.26 0.40−0.50 
glutamate/Cre (δ 2.35) 0.41±0.12 0.88±0.62 1.25±0.52 1.47±0.60 1.53±0.88 0.10−0.20 
alanine/Cre (δ 1.48) 0.27±0.18 0.42±0.39 0.96±0.55 1.15±0.77 0.75±0.32 <0.05 
valine/Cre (δ 1.05) 0.08±0.09 0.15±0.10 0.28±0.19 0.24±0.11 0.19±0.15 0.20−0.30 
lipid/Cre (δ 0.92) 0.22±0.28 1.33±0.89 3.59±2.98 3.35±2.19 2.82±3.30 0.10−0.20 
a) Abbreviations: Cre, creatine; NAA, N-acetyl aspartate; PC, phosphocholine; GPC, glycerophosphocholine; tCho, includes choline, PC and GPC; AST, 
astrocytoma; GBM, glioblastoma; MED, medulloblastoma. *, P<0.05, two-tailed ANOVA method. 
Table 5  Concentrations and ratios of metabolites showing significant differences between different grade tumors 
NMR method Significantly different concentrations and ratios of metabolite (P<0.05) Literature 
In vivo MRS NAA, Ala, Cre, tCho, mI (δ 3.56), Lac, Glu (or Gln, δ 3.7), Lip (δ 1.3), NAA/Cre, 
tCho/Cre, Lac/Cre, Gly/Cre, mI/tCho, mI/Cre, Ala/Cre 
Howe et al. [34], Tong et al. [14], Fayed et al. 
[15], Majos et al. [16,17], Meyerand et al. [38] 
In vitro NMR Ala, tCho, Tau, mI, Gly, Glu, Gly/Cre, Ala/Cre, tCho/Cre, Glu/Gln Kinoshita & Yokota [36], Roda et al. [41], 
Lehnhardt et al. [42] 
Ex vivo MAS Cre, Gln, Tau, PC, PE, Cho, mI (δ 4.06)/Cre Cheng et al. [43], Wilson et al. [44] 
Ex vivo MAS NAA, Lac, Cre, mI, Gly, NAA/Cre, Lac/Cre, mI/Cre, Gly/Cre, sI/Cre, Ala/Cre Our study 
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previous published studies on in vivo MRS [16,17,45], in 
vitro NMRS [18,41] and ex vivo MAS NMRS [44], the pre-
sent study demonstrated that HRMAS 1H NMR spectros-
copy combined with pattern recognition can increase the 
accuracy of grade classification and diagnosis of neuroepi-
thelial tumors, especially using the “leave-one-out” method. 
Further studies with larger sample sizes are needed to verify 
these findings.  
4  Conclusion 
HRMAS 1H NMR spectroscopy combined with pattern 
recognition can provide valuable metabonomic information 
on metabolites relevant to understanding the biology and 
pathology of brain tumors. It can also provide a potentially 
useful tool for the rapid and accurate grade classification of 
human brain tumors, which will help histopathologists to 
classify brain tumors more accurately, ultimately leading to 
the development of automatic diagnostic methods. 
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